NCT00220415View on ClinicalTrials.gov

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Partial Seizures With or Without Secondary Generalization
Interventions
DRUG

SPM 927

Trial Locations (1)

Unknown

Schwarz, Monheim

Sponsors

Lead Sponsor

UCB Pharma
All Listed Sponsors
lead

UCB Pharma

INDUSTRY

NCT00220415 - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization | Biotech Hunter | Biotech Hunter